TRUE Private Wealth Advisors Acquires 1,372 Shares of Johnson & Johnson $JNJ

TRUE Private Wealth Advisors lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,144 shares of the company’s stock after purchasing an additional 1,372 shares during the quarter. TRUE Private Wealth Advisors’ holdings in Johnson & Johnson were worth $4,757,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $48,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson in the first quarter valued at $52,000. Finally, Pandora Wealth Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Argus set a $210.00 price target on Johnson & Johnson in a research note on Wednesday, October 15th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Raymond James Financial raised their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Finally, Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $201.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $200.10 on Wednesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $200.30. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $482.11 billion, a price-to-earnings ratio of 19.31, a PEG ratio of 2.19 and a beta of 0.38. The stock’s 50-day simple moving average is $186.69 and its 200-day simple moving average is $170.77.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.